Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients

• Status: Completed
• Trial end date: 2016-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study is to find out whether treatment to prevent kidney rejection with belatacept in presence of Thymoglobulin induction and withdrawal of steroids will result in less delayed graft function or "sleepy kidney" after transplant than that seen in patients who get tacrolimus as their main drug to prevent rejection instead of belatacept. The investigators will also look at whether patients who get belatacept have the same, lesser or more problems that those who get tacrolimus.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Columbia University
• Treatments: Abatacept; Antilymphocyte Serum; Methylprednisolone; Methylprednisolone acetate; Methylprednisolone Hemisuccinate; Mycophenolate mofetil; Mycophenolic Acid; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate; Tacrolimus; Thymoglobulin

Criteria

Inclusion Criteria:

• Patients must have known Epstein-Barr virus (EBV) serostatus, and that status must be positive

• Adult patients ≥18 years of age, receiving a deceased donor kidney transplant at Columbia University Medical Center (CUMC)

• Patients with a PRA ≤ of 50

• Primary or re-transplant candidates (no more than 5th renal transplant)

• Deceased donor renal transplant recipients

• Candidates eligible for rATG induction

• Patients fully consented prior to transplantation

• Women of reproductive age who are willing to delay pregnancy for the duration of the study and use appropriate recommended contraception

Exclusion Criteria:

• Seronegative or unknown EBV serologic status (due to the risk of post-transplant lymphoproliferative disorder, PTLD), predominantly involving the central nervous system.

• Patients with tuberculosis who have not been treated for latent infection.

• Scheduled to undergo multi-organ transplantation

• Recipients of previous non-renal organ transplant

• Patient receiving 5th renal transplant at the time of screening.

• Patients with a PRA > 50

• Recipient is pre-emptive status.

• Recipient with positive flow crossmatch.

• History or known HIV

• Known hypersensitivity or contra-indications to Belatacept, Tacrolimus, Mycophenolate mofetil (cellcept), or mycophenolic acid

• Use of an investigational drug in the past 30 days before day of surgery

• Enrolled in a clinical trial other than the current

• Lactating or pregnant women

• Donor specific antibodies (DSA) identified at the time of transplantation

• ABO incompatible renal transplant